Methods for modulating the activation of a lymphocyte expressed G protein coupled receptor involved in cell proliferation, autoimmunity and inflammation

US6709830B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Owen N. Witte · West Hollywood, US
• Zhigang Weng · Cambridge, US
• Lu Q. Le · Los Angeles, US
• Janusz H. S. Kabarowski · Los Angeles, US
• Yan Xu · Dalian, CN
• Kui Zhu · Richmond Heights, US

Key dates

• Filing date: Feb 28, 2001
• Grant date: Mar 23, 2004
• Expiry date: Jun 13, 2022

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/726
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provided herein describes ligands and methods for modulating a G protein-coupled receptor (GPCR), designated G2A, a lymphocyte expressed receptor whose genetic ablation results in the development of autoimmunity. The present disclosure teaches that lysophosphatidylcholine (LPC) is a high affinity ligand for G2A and that sphingosylphosphorylcholine (SPC) is a lower affinity ligand for G2A. As G2A activation is shown to be involved in a variety of physiological processes including cell proliferation, autoimmunity and inflammation, methods which modulate its activity have a variety of diagnostic and therapeutic applications.